Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
1) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Atorvastatin 20 mg | Experimental | lipid lowering treatment |
|
| Cholestyramine 8 g | Experimental | lipid lowering treatment |
|
| Omega-3 (EPA+DHA) 2 g | Experimental | lipid lowering treatment |
|
| Atorvastatin 5 mg + Ezetimibe 10 mg | Experimental | lipid lowering treatment |
|
| Life style modification for management of dyslipidemia | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin 20 mg | Drug | The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups. |
| Measure | Description | Time Frame |
|---|---|---|
| Cholesterol efflux capacity (%) | [3H-cholesterol (µCi) in medium containing HDL/(3H-cholesterol {µCi} in medium containing HDL+µCi of 3H-cholesterol {µCi} in cells)] x 100 | Change of HDL functions from baseline to 8 weeks |
| Endothelial NO production (Arbitrary unit) | measured with nitrate assay kit and expressed as relative amount compared to control (no HDL treatment sample) | up to 8 weeks |
| VCAM-1 expression (Arbitrary unit) | western blotting of VCAM-1 protein and expressed as relative amount compared to control (no HDL treatment sample) | up to 8 weeks |
| ROS generation (Arbitrary unit) | fluorescence intensity measurement using dichlorodihydrofluorescein diacetate and expressed as relative amount compared to control (no HDL treatment sample) | up to 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| ApoA-I | quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample) | Change of HDL associated proteins from each patient at baseline and at 8 weeks |
| ApoA-II |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Cardiology, Department of Internal Medicine, | Seoul | 03722 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28245873 | Derived | Lee CJ, Choi S, Cheon DH, Kim KY, Cheon EJ, Ann SJ, Noh HM, Park S, Kang SM, Choi D, Lee JE, Lee SH. Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. Lipids Health Dis. 2017 Feb 28;16(1):49. doi: 10.1186/s12944-017-0433-6. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D002792 | Cholestyramine Resin |
| D004281 | Docosahexaenoic Acids |
| D000069438 | Ezetimibe |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cholestyramine 8 g | Drug | The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups. |
|
| Omega-3 2g | Drug | The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups. |
|
| Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg | Drug | The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups. |
|
| Lifestyle modification | Behavioral | The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups. |
|
quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)
| Change of HDL associated proteins from each patient at baseline and at 8 weeks |
| ApoC-I | quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample) | Change of HDL associated proteins from each patient at baseline and at 8 weeks |
| ApoC-II | quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample) | Change of HDL associated proteins from each patient at baseline and at 8 weeks |
| ApoC-III | quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample) | Change of HDL associated proteins from each patient at baseline and at 8 weeks |
| D006538 |
| Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D011137 | Polystyrenes |
| D010969 | Plastics |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |
| D015525 | Fatty Acids, Omega-3 |
| D004042 | Dietary Fats, Unsaturated |
| D004041 | Dietary Fats |
| D005223 | Fats |
| D005231 | Fatty Acids, Unsaturated |
| D005395 | Fish Oils |
| D009821 | Oils |
| D001384 | Azetidines |
| D001385 | Azetines |